You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

SHINGRIX demonstrated an effect on postherpetic neuralgia (PHN)

By helping prevent shingles, SHINGRIX reduced the incidence of developing PHN 1*

SHINGRIX was shown to significantly reduce the incidence of developing PHN in subjects ≥70 vs. placebo 2*

8,250 PATIENTS ≥70 YEARS OF AGE RECEIVED SHINGRIX 1
4 CASES OF PHN WERE REPORTED IN THIS AGE GROUP 
1

The benefit of SHINGRIX on PHN can be attributed to the effect of the vaccine on the prevention of HZ. A further reduction of PHN incidence in subjects with confirmed HZ could not be demonstrated due to the limited number of HZ cases in the vaccine group. 1

* Pooled data from study ZOE-50 and ZOE-70. Modified Total Vaccinated Cohort (mTVC) was the primary efficacy analysis and included all subjects randomized in the study who received a second dose of the vaccine and did not develop a confirmed case of shingles within one month after the second dose. Subjects were followed prospectively development of PHN. PHN was defined as shingles-associated pain rated as 3 or greater on a 0-10 scale occurring or persisting at least 90 days following the onset of rash using the Zoster Brief Pain Inventory questionnaire.

† SHINGRIX is not indicated for prevention of primary varicella infection or for the treatment of herpes zoster (HZ) or postherpetic neuralgia (PHN). 

References:

  1. SHINGRIX Product Monograph. GlaxoSmithKline Inc., October 13, 2017.
  2. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016 Sep;375(11):1019-32.